Studies have shown that AMOT activates the ERK1/2 pathway to drive cell proliferation in ER+ breast cancer [54], and that miR-205-5p inhibits cell growth by direct targeting of AMOT in MCF-7 breast cancer cells [55]. This evidence concerns the gene MAPK3 and breast carcinoma.